Navigation Links
Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
Date:3/10/2008

EMERYVILLE, Calif., March 10 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today results from two independent physician surveys which showed MF101 could become first-line treatment for menopausal vasomotor symptoms (hot flashes). In both qualitative and quantitative studies, 124 physicians board certified in internal medicine or obstetrics and gynecology specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes. In addition, 92% of physicians reported they would prescribe MF101 before prescribing an antidepressant agent for hot flashes.

"These results confirm what we have believed for over a decade. Both physicians and women are eagerly awaiting a safe and new alternative drug for the treatment of menopausal symptoms," said Mary Tagliaferri, M.D., Bionovo's President and CMO. "The multiple medical risks associated with estrogen therapies make these drugs undesirable, and the antidepressant agents currently used off label for this indication are poorly tolerated due to their many side effects. In contrast, our lead drug candidate, MF101, showed in a Phase 2 study that it is effective at alleviating hot flashes and is extremely well tolerated due to a very favorable safety profile."

In addition to placing MF101 at the top of the list of treatment options for menopausal symptoms, physicians also reported the following:
-- The accepted threshold for efficacy of a drug for vasomotor symptoms is

a 58% reduction in moderate to severe hot flashes, and,

-- The number one concern for women when considering treatment options for

menopausal symptoms is the risk of cancer.

-- Many women have foregone treatment of hot flashes, even moderate to

severe hot flashes, because of the side effects and risks of current

treatments.

"These independent physician studies provide us with further evidence that if available, MF101 can be a blockbuster drug once it hits the market," said Isaac Cohen, O.M.D., Chairman and CEO of Bionovo. "A safe and effective drug should be able to earn a large share of the $6-7 Billion of demand that existed in the past for this indication."

Complete results from the independent physician surveys are being prepared for publication.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Physicians Reconsider Implications of Enhance Trial
6. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
7. Physicians Will Benefit from Medical Software Advice Website
8. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
11. St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  NanoViricides, ... that it has entered into an agreement with ... its nanoviricides® drug candidates in standard animal models ... Romanowski , Research Director. Dr. Romanowski has extensive ... discovery. --> Eric Romanowski , ...
(Date:2/11/2016)... -- North America , Europe ... global market is expected to reach USD 20,190.1 Million by 2020 ... 10.2%. --> North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> According to a new market research ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced ... , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking ... During his session, “ Coding for Care: Using Data Analytics for Risk Adjustment ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for ... health and wellness best practices in the past couple of decades, and food ... American Heart Month, which acts as an exceptional opportunity to revise food labels ...
Breaking Medicine News(10 mins):